Get started
Author

Sergio Muñoz

Observed names: S. Muñoz-Martínez, S.G. Muñoz-Martínez, Sergio G. Muñoz-Martinez, Sergio G. Muñoz-Martínez, Sergio G. Muñoz‐Martínez, Sergio Munoz, Sergio Muñoz, Sergio Muñoz-Martinez, Sergio Muñoz-Martínez, Sergio Muñoz‐Martinez, Sergio Muñoz‐Martínez
Institutions: Vall d'Hebron Institut de Recerca, Centro de Investigación Biomédica en Red, Hospital Clínic de Barcelona, Vall d'Hebron Hospital Universitari, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, Centro Médico ABC, Consorci Institut D'Investigacions Biomediques August Pi I Sunyer
Observed institutions: Universidad de La Frontera, Universitat Autònoma de Barcelona, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Vall d'Hebron Institut de Recerca, Centro de Investigación Biomédica en Red, Hospital Clínic de Barcelona, Vall d'Hebron Hospital Universitari, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, Centro Médico ABC, Fundació Clínic per a la Recerca Biomèdica, Consorci Institut D'Investigacions Biomediques August Pi I Sunyer, Universitat de Barcelona
ORCID: 0000-0003-0663-0575
Observed ORCID: 0000-0003-0663-0575
OpenAlex ID: A5101757604
Gallstones and gallbladder cancer‐volume and weight of gallstones are associated with gallbladder cancer: A case‐control study
2006 · Iván Roa, Gilda Ibacache, et al. · Journal of Surgical Oncology · 83
Hepatocellular carcinoma downstaging for liver transplantation in the era of systemic combined therapy with anti‐VEGF/TKI and immunotherapy
2022 · Nguyen H. Tran, Sergio Muñoz, et al. · Hepatology · 75
Assessing the impact of COVID-19 on liver cancer management (CERO-19)
2021 · Sergio Muñoz-Martínez, Victor Sapena, et al. · JHEP Reports · 63
Effectiveness of cryotherapy treatment for cervical intraepithelial neoplasia
2008 · Silvana Luciani, Miguel Gonzales, et al. · International Journal of Gynecology & Obstetrics · 55
Current state-of-the-art and gaps in platform trials: 10 things you should know, insights from EU-PEARL
2023 · Franz Koenig, Cécile Spiertz, et al. · EClinicalMedicine · 48
PDF
Phenotypes of Metabolic Dysfunction–Associated Steatotic Liver Disease–Associated Hepatocellular Carcinoma
2024 · Jesús Rivera-Esteban, Sergio Muñoz-Martínez, et al. · Clinical Gastroenterology and Hepatology · 41
Liver cancer risk after HCV cure in patients with advanced liver disease without non-characterized nodules
2021 · Marco Sanduzzi-Zamparelli, Zoe Mariño, et al. · Journal of Hepatology · 41
Outcome of patients with HCC and liver dysfunction under immunotherapy: a systematic review and meta-analysis
2023 · Ismael El Hajra, Marco Sanduzzi-Zamparelli, et al. · Hepatology · 35
PDF
Portopulmonary Hypertension: An Updated Review
2023 · Erick A. Jasso-Baltazar, Gonzalo A. Peña-Arellano, et al. · Transplantation Direct · 32
Current pharmacological treatment of hepatocellular carcinoma
2021 · Sergio Muñoz-Martínez, Gemma Iserte, et al. · Current Opinion in Pharmacology · 23
PDF
Atypical manifestations of hepatitis A virus infection
2018 · S.G. Muñoz-Martínez, H.A. Díaz-Hernández, et al. · Revista de Gastroenterología de México (English Edition) · 22
PDF
Inactivation of tumor suppressor gene pten in early and advanced gallbladder cancer
2015 · Iván Roa, Gonzalo de Toro, et al. · Diagnostic Pathology · 22
PDF
Outcome of liver cancer patients with SARS‐CoV‐2 infection: An International, Multicentre, Cohort Study
2022 · Sergio Muñoz‐Martínez, Victor Sapena, et al. · Liver International · 20
PDF
Prognostic factors of phyllodes tumor of the breast
2006 · Juan Carlos Roa, Oscar Tapia, et al. · Pathology International · 19
Manifestaciones atípicas de la infección por el virus de la hepatitis A
2018 · S.G. Muñoz-Martínez, H.A. Díaz-Hernández, et al. · Revista de Gastroenterología de México · 15
Prevalence and Risk Factors of MASLD and Liver Fibrosis amongst the Penitentiary Population in Catalonia: The PRISONAFLD Study
2023 · Jesús Rivera-Esteban, Alba Jiménez-Masip, et al. · Journal of Clinical Medicine · 11
PDF
Predicting Hepatic Decompensation in Patients With Metabolic Dysfunction Associated Steatotic Liver Disease‐Related Cirrhosis: The ABID ‐ LSM Model
2025 · Luis Calzadilla Bertot, Anna Sòria, et al. · Alimentary Pharmacology & Therapeutics · 8
PDF
Cholangiocarcinoma: early detection and screening in high-risk population
2022 · Sergio Muñoz-Martínez, Jordi Rimola, et al. · Hepatoma Research · 8
PDF
Activated Lymphocytes and Increased Risk of Dermatologic Adverse Events during Sorafenib Therapy for Hepatocellular Carcinoma
2021 · Josep Corominas, Victor Sapena, et al. · Cancers · 8
PDF
The rate and predictors of recompensation in patients with decompensated cirrhosis due to metabolic dysfunction–associated liver disease (MASLD)
2026 · Alba Jiménez-Masip, M. Teresa Broquetas, et al. · Hepatology Communications · 7
Risk of Treatment Failure and Death after Ablation in Hepatocellular Carcinoma Patients—A Multiparametric Prediction
2023 · Sergio Muñoz-Martínez, Victor Sapena, et al. · Cancers · 6
PDF
Hipertensión portopulmonar: Revisión actualizada
2016 · Nielzer Rodríguez-Almendros, Liz N. Toapanta-Yanchapaxi, et al. · Archivos de cardiología de México · 6
ERCC1 (excision repair cross-complementing 1) expression in pT2 gallbladder cancer is a prognostic factor.
2011 · Iván Roa, Xabier de Aretxabala, et al. · PubMed · 6
PDF
Autoantibodies are associated with worse outcomes in MASLD
2025 · Anna Soria, Alba Díaz, et al. · JHEP Reports · 5
PDF
Clinical Trial: Early Nivolumab Addition to Regorafenib in Patients With Hepatocellular Carcinoma in Second‐Line (The GOING Trial)
2026 · Marco Sanduzzi‐Zamparelli, Ana Matilla, et al. · Alimentary Pharmacology & Therapeutics · 4
Works count: 43
Citation count: 671
H-index: 15
I10-index: 16
Year
Topic
Type